Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity

Johnson & Johnson (JNJ) sold off roughly 2% in mid-July after reporting second-quarter earnings, but the dip may offer an entry point. The healthcare giant posted $25.31 billion in revenue for Q2, up 6.8% year-over-year, and delivered earnings of $2.90 per share, topping consensus estimates. Management raised full-year guidance following the beat.

The company holds Dividend King status—50-plus consecutive years of dividend increases—and is preparing to spin off its orthopedics business. Despite the earnings strength, shares retreated on continued talc litigation overhang, which remains a headline risk but has yet to derail the fundamental trajectory.

Analysts cited in the Investing.com report view the pullback as a buying opportunity, pointing to JNJ's diversified portfolio across pharmaceuticals, medical devices, and consumer health, plus a robust pipeline that supports long-term growth. The revenue beat and guidance raise underscore operational momentum even as legal concerns weigh on sentiment.